OTCMKTS:CBIS - Cannabis Science Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.0502 0.00 (0.00 %)
(As of 07/23/2018 11:44 AM ET)
Previous Close$0.0512
Today's Range$0.05 - $0.0510
52-Week Range$0.0311 - $0.1397
Volume1.59 million shs
Average Volume13.73 million shs
Market Capitalization$190.59 million
P/E RatioN/A
Dividend YieldN/A
Beta-3.5
Cannabis Science logoCannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid-based pharmaceutical products primarily in the United States. The company is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. Its drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions. In addition, the company offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, benefits of medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug; and a research collaboration agreement with Dana-Farber Cancer Institute, Inc. to develop and investigate the use of cannabinoids to cure various cancers, as well as with Stellenbosch University to treat chronic pelvic pain associated with pelvic inflammatory disease in women, chronic prostatitis in men, and other chronic pain associated with other indications. The company was formerly known as Gulf Onshore, Inc. and changed its name to Cannabis Science, Inc. in April 2009. The company was incorporated in 1996 and is based in Irvine, California. Cannabis Science, Inc. is a subsidiary of Weedmaps Media, Inc.

Receive CBIS News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryCannabis
SectorMedical
SymbolOTCMKTS:CBIS
CUSIPN/A
Phone+1-888-8890888

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-151,408.60%
Return on EquityN/A
Return on Assets-590.52%

Miscellaneous

EmployeesN/A
Outstanding Shares2,520,000,000
Market Cap$190.59

Cannabis Science (OTCMKTS:CBIS) Frequently Asked Questions

What is Cannabis Science's stock symbol?

Cannabis Science trades on the OTCMKTS under the ticker symbol "CBIS."

How were Cannabis Science's earnings last quarter?

Cannabis Science Inc (OTCMKTS:CBIS) released its quarterly earnings data on Tuesday, July, 28th. The company reported $0.00 earnings per share for the quarter. View Cannabis Science's Earnings History.

What is the consensus analysts' recommendation for Cannabis Science?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cannabis Science in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Cannabis Science's key competitors?

Who are Cannabis Science's key executives?

Cannabis Science's management team includes the folowing people:
  • Mr. Raymond C. Dabney, Co-Founder, Chairman, CEO & Pres (Age 53)
  • Mr. Benjamin C. K. Tam, Chief Financial Officer, Sec. and Director (Age 66)
  • Mr. Robert James Kane, Chief Operating Officer, VP of Investor Relations and Director (Age 42)
  • Dr. Allen A. Herman M.B., Ch.B., Ph.D., Chief Medical Officer & Member of Scientific Advisory Board (Age 63)
  • Mr. Mario Lap, Pres of European Operations & Director (Age 66)

Has Cannabis Science been receiving favorable news coverage?

News stories about CBIS stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cannabis Science earned a media sentiment score of 0.11 on Accern's scale. They also gave headlines about the company an impact score of 45.88 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Cannabis Science?

Shares of CBIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cannabis Science's stock price today?

One share of CBIS stock can currently be purchased for approximately $0.0502.

How big of a company is Cannabis Science?

Cannabis Science has a market capitalization of $190.59 million.

How can I contact Cannabis Science?

Cannabis Science's mailing address is 19800 Macarthur Blvd Ste 300, IRVINE, CA 92612-2479, United States. The company can be reached via phone at +1-888-8890888.


MarketBeat Community Rating for Cannabis Science (OTCMKTS CBIS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  168
MarketBeat's community ratings are surveys of what our community members think about Cannabis Science and other stocks. Vote "Outperform" if you believe CBIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBIS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.